PROBIAL BABY Colic
Pediatrics
- Targeted inhibition of coliform bacteria isolated from colicky infants
- Supports mucosal functionality
- Anti-inflammatory properties
Bifidobacterium breve BR03 (DSM 16604)
Lacticaseibacillus rhamnosus GG (ATCC53103)
Food supplement with probiotic strains.
Infantile colic can affect up to one in three babies during the first few months of life. PROBIAL® BABY Colic is formulated with highly researched probiotic strains known for their effectiveness in managing gaseous colic in newborns:
Bifidobacterium breve BR03: Colicky infants often have a higher concentration of gas-producing coliforms compared to healthy babies. B. breve combats these pathogens through the secretion of organic acids and antimicrobial substances [1,2]. In vitro studies have demonstrated BR03's ability to inhibit pathogenic E. coli [3-5]. Additionally, when used in conjunction with another B. breve strain, BR03 significantly reduced the growth of Enterobacteriaceae isolated from colicky infants and decreased total fecal coliforms [6].
Lacticaseibacillus rhamnosus GG: This strain is among the most extensively studied probiotics, especially in the context of pediatric diarrhea. It is supported by over 1000 publications and 300 clinical studies, highlighting its significance and reliability in addressing gastrointestinal issues in infants [7].
1. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47
2. Bozzi Cionci N, et al. Therapeutic Microbiology: The Role of Bifidobacterium breve as Food Supplement for the Prevention/Treatment of Paediatric Diseases. Nutrients. 2018 Nov 10;10(11):1723. doi: 10.3390/nu10111723
3. Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214
4. Del Piano M., et al. In vitro sensitivity of probiotics to human pancreatic juice. J Clin Gastroenterol. 2008;42 Suppl 3 Pt 2:S170-S173. doi:10.1097/MCG.0b013e3181815976.
5. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32
6. Mogna L. et al. Capability of the two microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to colonize the intestinal microbiota of children. J Clin Gastroenterol. 2014;48 Suppl 1:S37-S39. doi:10.1097/MCG.0000000000000234
7. Capurso L. Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol. 2019 Mar;53 Suppl 1:S1-S41. Doi: 10.1097/MCG.0000000000001170
